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Abstract
Earlier studies of androgen-receptor (AR) expression using frozen prostate tissue, and later studies
using archived specimens, produced the consensus that ligand-stabilized AR is nuclear, AR
expression is similar in benign epithelia and stroma, AR expression is greater in secretory epithelia
than basal cells, and AR expression is more variable in prostate cancer (CaP) than in benign prostatic
hyperplasia (BPH). Accurate measurement of AR expression remains technically challenging but
necessary to evaluate the relevance of ARs to clinical CaP. Recent studies demonstrated that AR
expression in epithelia and stroma may be prognostic in clinically localized CaP, and AR expression
may play a role in racial differences in CaP mortality and predict response to androgen deprivation
therapy. High levels of AR and AR-regulated gene expression indicate a central role for AR in growth
regulation of castration-recurrent CaP. New treatments for the lethal phenotype of CaP require better
understanding of AR transactivation during androgen deprivation therapy.
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Androgens are necessary for the development and growth of the prostate and for the
development, growth and progression of prostate cancer (CaP). An American man is diagnosed
with CaP every 3 minutes,[1] and the worldwide incidence of CaP is increasing an estimated
1.1% annually.[2] Despite increased use of digital rectal examination and serum prostate-
specific antigen (PSA) measurement for early detection, approximately 30% of men treated
with curative intent suffer CaP recurrence. These men, and those who present with locally
advanced or metastatic CaP, can be palliated by androgen deprivation therapy (ADT), which
causes regression of androgen-dependent CaP through programmed cell death.[3] Although
there are many methods for medical and surgical ADT, the results of ADT remain unimproved
since its discovery more than 60 years ago.[4] More than 80% of men with disseminated CaP
demonstrate clinical or biochemical response that is associated with a mean life expectancy of
approximately 3.5 years, in contrast to non-responders or untreated patients who live an average
of 9 months. Regardless of the androgen responsiveness of incurable CaP, almost all patients
succumb to castration-recurrent CaP because it responds poorly to all known therapies, and
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approximately 27,050 American men, or one man every 17 minutes, will die from CaP this
year.[1]
Discovery of the AR simultaneously by two groups at University of Chicago[5] and University
of North Carolina[6] and development of AR-specific antibodies[7,8] made the study of AR
protein expression in prostate tissue practical. Although AR expression is diminished
immediately after ADT that induces clinical remission in most patients, castration-recurrent
CaP expresses levels of AR protein similar to those found in androgen-stimulated benign
prostate and CaP. This observation suggests that the AR may be as important for growth
regulation in castration-recurrent CaP as it is in androgen-stimulated benign prostatic
hyperplasia (BPH) and CaP. The clinical relevance of inter-individual and population variation
of AR protein expression cannot be understood unless AR protein expression can be assessed
accurately and correlated with the development and progression of benign and malignant
prostate diseases. Since molecular and biochemical studies of AR using human benign CaP
cell lines probably more often confuse than inform, this chapter examines the measurement of
AR protein expression in clinical specimens and determines whether AR protein expression
has clinical relevance to patients suffering from clinically localized or advanced CaP.
AR IN CLINICALLY LOCALIZED PROSTATE CANCER
AR is unique among the steroid hormone receptors in that ligand binding stabilizes AR rather
than earmarking it for degradation. AR ligand binding demonstrates a threshold effect whereby
non-castrate levels of testicular androgens produce transactivation, and levels above the
threshold produce little additional AR activity. By logical extension, normal androgen levels
in an adult male should allow AR transactivation and expression of AR-regulated genes.
However, the level of AR protein varies within epithelial and stromal nuclei of benign and
malignant prostate tissue, and the biologic effects of this variation within the microenvironment
of the prostate remain unknown. Relatively few data have been reported that allow one to reach
conclusions about the role of AR in the development or progression of CaP. The scarcity of
work in this area results from many factors. First, the discovery of AR occurred less than 20
years ago.[5,6] Second, quantitation of AR protein expression is technically difficult and labor-
intensive. Third, the heterogeneity of CaP renders study of diagnostic prostate biopsies and
even radical prostatectomies problematic. Fourth, archival CaP tissue must be stored a long
time to link it to clinical outcome endpoints due to the long natural history of clinically localized
CaP. Time to clinical endpoints is lengthened further due to PSA early detection programs
(PSA allows detection of CaP approximately 10 years before palpable changes occur on
prostate exam.)[9] Finally, CaP treatment outcomes are confused by a high rate of deaths from
other causes and inclusion of incidental CaP in more recent series.
ANDROGEN-RECEPTOR EXPRESSION IN THE EPITHELIA OF CLINICALLY
LOCALIZED PROSTATE CANCER
The first study that examined the relationship between AR concentration and Gleason grade
and clinical stage was reported in 1986.[10] Since AR antibodies had not yet been developed,
biochemical measurement of AR content was required. Tumor specimens were obtained by
transurethral resection (TURP) and clinical staging was by digital rectal exam. AR content and
histological grade did not correlate, but early stage CaP (n = 5, clinical stage <T3 but one man
was M1) had significantly lower AR levels than CaP of higher stage (n = 5, all men T3M1).
The authors suggested that greater androgenic stimulation due to higher levels of AR protein
provided a growth advantage that resulted in higher stage of tumor at presentation. These
seminal observations remain supported many years and studies later.
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Perhaps the first study of AR using immunohistochemistry was reported in 1990.[11] Frozen
diagnostic prostate needle biopsies from 63 cases of untreated CaP, eight cases of castration-
recurrent CaP, and nine cases of BPH were studied using a monoclonal AR antibody. BPH
was characterized by AR immunostaining of nuclei (but not cytoplasm) of epithelial and
stromal cells, but basal cells did not immunostain for AR. In CaP, AR immunostaining also
was confined to nuclei; however, greater variation was described: AR-positive and AR-
negative cells intermingled more in CaP than in BPH. In castration-recurrent CaP, the
population of AR-positive cells was decreased. Although this study was the first to report an
association between AR expression and histological grade of CaP, one contemporaneous study
[12] was consistent with this report, but seven other studies[10,13–18] showed no correlation
between Gleason grade and AR immunostaining.
The first study that carefully compared AR immunostaining in CaP and BPH from the same
prostatectomy specimen and BPH from patients without CaP was reported in 1993.[19] Tissue
preservation of immunoreactivity was enhanced by mounting tissue onto rat-liver homogenate
as an adhesive and rapid freezing in isopentane cooled by liquid nitrogen. AR immunostaining
was characterized by both intensity of, and variation in, intensity of immunostaining using a
visual scoring index. High quality immunostaining and careful visual assessment of
immunostaining demonstrated that BPH had similar nuclear AR protein expression whether
obtained from CaP patients or patients without CaP, and that CaP had decreased intensity and
hence greater heterogeneity of AR immunostaining.
Tilley’s group was the first to report, in 1998, a method for image analysis that sought to
improve upon visual assessment of AR immunostaining.[20] Percentage of nuclei
immunostained for AR were estimated based upon image analysis of areas of benign or
malignant epithelia or stroma; individual nuclei were not evaluated. An affinity-purified
polyclonal AR antibody was used to study 30 patients with clinically localized CaP (10 stage
A and 20 stage B according to the Whitmore–Jewett system) and frozen research samples were
obtained by TURP (n = 24) or radical prostatectomy (n = 6). AR immunostaining in malignant
or benign epithelia within the same section appeared similar, with heterogeneous
immunostaining composed of weakly to strongly positive nuclear immunoreactivity in the
majority of cells. In contrast, stromal cells displayed focal immunoreactivity with regions of
AR-immunopositive stromal cells interspersed with regions of negatively immunostained
stromal cells. These authors were the first to report that AR immunostaining appeared similar
in early CaP and benign prostate tissue. These results were contrasted with studies of advanced
CaP from their own laboratory[21] and from others[22–25] where reduced AR
immunoreactivity and increased heterogeneity of cellular staining was observed. They
attributed the similar findings in early CaP and benign prostate tissue to the lack of development
of greater genetic instability and altered androgen sensitivity, which they believed a
characteristic of advanced CaP, especially after administration of ADT.[6]
The first careful study of AR expression using archival prostate specimens was reported in
1999.[16] Sixteen radical prostatectomy specimens from patients with clinically localized CaP
and 16 TURP specimens from men with BPH were double-labeled with monoclonal AR
antibody F39.4.1 and anti-cytokeratin monoclonal 13bE12. The basal epithelial cell layer was
visualized in BPH and high-grade prostatic intraepithelial neoplasia (HGPIN), whereas no
basal cells were seen in malignant glands. Epithelial cells of CaP glands showed higher AR
mean optical density (MOD) than BPH (0.11 ± 0.01 versus 0.07 ± 0.01, P < 0.05). HGPIN
identified in ten radical prostatectomy specimens showed AR immunostaining similar to that
in BPH (0.05 ± 0.02). BPH from TURP specimens (0.25 ± 0.02) showed significantly higher
AR immunostaining intensity compared to BPH from radical prostatectomy specimens (P <
0.01). Differences in AR protein preservation due to differences in tissue procurement and/or
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tissue fixation preclude study of different sources of tissues – biopsy versus TURP versus
radical prostatectomy and frozen versus archival.
ANDROGEN-RECEPTOR EXPRESSION IN THE STROMA OF CLINICALLY
LOCALIZED PROSTATE CANCER
In 1996, our group reported that AR immunostaining of frozen radical prostatectomy
specimens was diminished in stroma compared to epithelia in both BPH and CaP, and that the
decreased AR expression described previously in epithelial nuclei of CaP compared to BPH
was also characteristic of the stroma of both tissue types.[14] In 1998, the Tilley laboratory
was the first to call attention to variation in AR immunostaining within the stroma; AR
immunostaining was diminished in the stroma adjacent to malignant glands.[20] These clinical
observations were supported by preclinical data using the Cunha model,[26,27] where tumor
stroma supported carcinogenesis of the overlying epithelium. Furthermore, Rowley[28] and
Arnold and Isaacs[29] reviewed the data that supported the hypothesis that stroma produces a
reciprocal inhibition of epithelia and that the suppressive effect of the stroma is lost in CaP and
contributes to CaP progression. AR immunostaining in stroma was more carefully evaluated
by Olapade-Olaopa et al[30] using a monoclonal AR antibody and archival TURP and radical
prostatectomy specimens from 17 patients with BPH and 39 age-matched patients with CaP.
Another new method for visually assessing AR expression was introduced where the number
of cells strongly positive within a given area was expressed as a percentage. A final score was
given as negative if no cells stained, weak if 1–33% of cells immunostained, moderate if 34–
66% of cells immunostained, and strong if >66% of cells immunostained. CaP epithelium had
greater heterogeneity and a lower overall level of expression of AR compared to benign prostate
tissue. In HGPIN, nuclear immunostaining in the epithelia was intermediate between that of
benign and malignant glands. AR immunostaining was more heterogeneous in CaP compared
to BPH. AR immunostaining was absent in the nuclei of stromal cells surrounding CaP glands,
and this absence was most pronounced in poorly differentiated CaP. AR immunostaining of
stroma surrounding HGPIN was reduced similarly. AR was depleted from stroma adjacent to
benign glands that were close to CaP glands and was expressed to a greater extent the more
distant the benign epithelia was from adjacent cancer.
A third and independent group confirmed the observations that AR immunostaining was
reduced in the ‘tumor stroma’.[15] Henshall et al studied 96 radical prostatectomies from
patients treated for clinically localized CaP using the same monoclonal AR antibody. They
proposed another scoring system for AR immunostaining: 500 epithelial cells and 200–250
stromal cells were evaluated in each tissue sample by three individuals, which included one
pathologist. AR expression was categorized in the epithelia and periepithelial stroma as ≤ or
>30% AR-positive. They reported that concurrent high AR expression in CaP and low AR
expression in the periepithelial stroma was associated with higher clinical stage, higher
pretreatment PSA, and earlier CaP recurrence. These data provided the first ever evidence for
an association between AR expression in the stromal microenvironment and clinical outcome
in CaP patients treated by radical prostatectomy. Both groups[15,30] reported that the stroma
surrounding HGPIN also lacked AR expression, which suggested that altered AR expression
in the stroma is an early event in CaP development and progression.
A more precise characterization of AR immunostaining by the Tilley group[18] extended the
observations of Henshall et al.[15] Fifty-three patients underwent radical prostatectomy and
were followed for a minimum of 3 years. AR was recognized using an affinity-purified rabbit
polyclonal AR antibody and current antigen retrieval techniques. AR immunostaining was
assessed visually and using video image analysis. Almost all CaP demonstrated nuclear AR
immunoreactivity. In contrast to most observers and prior studies from this group, visual
assessment indicated that the percentage of AR-positive cells was significantly lower in benign
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(85%) than malignant (94%) epithelial cells. In the stroma, the percentage of AR-positive cells
in the peritumoral stroma was reduced compared to the stroma adjacent to benign glands. Image
analysis confirmed the visual assessment that AR-positive nuclear area was lower in benign
than in malignant epithelia. The surprising finding was that lower AR immunostaining was
associated with significantly fewer PSA relapses (6%) compared to higher AR immunostaining
(42%). High AR-positive epithelial nuclear area was associated with extra-prostatic cancer
(pT3) but not higher Gleason scores or preoperative serum PSA levels. Relapse became even
more likely when AR positivity was <45% in the peritumoral stroma. Thus, two groups acting
independently, using different specimens and different methods of analysis, associated poor
treatment outcome with high levels of AR expression in CaP epithelia and low levels of AR
in peritumoral stroma. These findings suggest that increased androgenic stimulation of
epithelia associated with reduced apoptotic influence coming from the stroma may produce a
more aggressive phenotype of CaP. However, these findings lack clinical relevance until
pretreatment biopsies are studied instead of radical prostatectomy specimens. These findings
may also be relevant to racial differences in AR levels between African-American and
Caucasian-American men, which is described more fully below. Increased AR levels in CaP
epithelia, especially in more advanced CaP, may be associated with increased expression of
AR-regulated genes and increased tumor growth and/or metastasis.
ANDROGEN RECEPTOR AND RACIAL DIFFERENCES IN PROSTATE
CANCER
Although the frequency of incidental CaP is similar between races,[31,32] African Americans
have a higher incidence of, and greater mortality from, CaP than Caucasian Americans. Data
from the SEER database (1993–1997) show that the incidence of invasive CaP is greater in
African Americans than Caucasian Americans: 1.9 times greater in men <65 years of age and
1.6 times greater in men ≥65 years of age.[33] In men <65 years of age, the CaP mortality rate
for African Americans is 3.1 times that of Caucasian Americans. In men ≥65 years of age, the
CaP mortality rate for African Americans is 2.3 times that of Caucasian Americans. [33]
Difference in CaP incidence between men of different geographic origin is not unique to the
United States; for example, in Sao Paulo, Brazil, CaP is 1.8 times more common in Brazilians
of African than European origin.[34]
AR protein expression was evaluated in malignant and benign prostate tissue from African
Americans and Caucasian Americans who underwent radical prostatectomy for clinically
localized CaP.[35] Archived radical prostatectomy specimens obtained from 25 Caucasian
Americans and 25 African Americans had AR protein antigen retrieved and immunostained.
AR protein expression from CaP and benign tissue was assessed using two methods. Visual
scoring suggested that AR immunostained more intensely in both malignant and benign
epithelial nuclei in African Americans than Caucasian Americans. Automated digital color
video image analysis was used to measure percent positive nuclei and the intensity of
expression (MOD) in each nucleus. In African Americans compared to Caucasian Americans,
malignant nuclei were 27% more likely immunostained for AR (P = 0.005), and among
immunopositive nuclei, AR protein expression was 81% greater (P = 0.002). Among
immunopositive benign nuclei, AR protein expression was 22% greater in African Americans
compared to Caucasian Americans (P = 0.027). Racial differences in AR protein expression
were not explained by age, pathologic grade or stage. CaP may occur at a younger age and
progress more rapidly in African Americans than Caucasian Americans due to racial
differences in AR, but these findings must be confirmed by others, and tissue expression of
AR-regulated genes must be evaluated in men of both races.
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ANDROGEN-RECEPTOR EXPRESSION AND PROGNOSIS IN CLINICALLY
LOCALIZED PROSTATE CANCER
In addition to the data presented above on the prognostic significance of AR immunostaining
in the epithelia and stroma, two other recent reports more critically evaluated AR as a biomarker
of treatment response. The Baylor SPORE created a radical prostatectomy tissue microarray
that was studied using a monoclonal AR antibody.[36] AR immunostaining was assessed
visually and scored semi-quantitatively. An intensity score was assigned and multiplied by a
labeling frequency score and AR expression reduced to a dichotomous variable, either low or
high level. AR expression was weakly but significantly correlated with stage and Gleason score
but did not correlate with preoperative PSA level or surgical margin status. Of greatest interest
is that they reported correlation between cellular proliferation measured using Ki-67 labeling
index and AR level of expression. Furthermore, they found that patients with high-level AR
expression had significantly reduced biochemical progression-free survival compared to those
with low-level AR expression. AR expression remained an independent prognostic indicator
of biochemical progression-free survival on multivariate analysis. The relationship between
Ki-67 and AR expression and outcome is not surprising, since others have reported a
relationship between biochemical progression-free survival and Ki-67.[37]
Most recently, the Tilley group[38] reported that elevated levels of HER-2/neu and AR were
associated with adverse outcomes after radical prostatectomy. HER-2/neu and AR
immunoreactivity were evaluated using quantitative video image analysis of tissue regions in
archived prostatic tissues obtained from 53 men with clinically localized CaP who underwent
radical prostatectomy; 70% of tumors exhibited high levels of HER-2/neu immunostaining,
and 68% of tumors had elevated AR levels. Patients with high levels of both HER-2/neu and
AR had the highest rate of PSA failure (56%, 15/27) compared with no PSA failures among
seven patients with low levels of both HER-2/neu and AR (log rank statistic 7.69, P = 0.021).
Concurrent high levels of HER-2/neu and AR expression were associated with high
pathological stage (P = 0.027) and development of metastatic disease (P = 0.022). These
findings suggest that the HER-2/neu and AR signaling pathways may contribute to
development of metastatic disease.
ANDROGEN RECEPTOR IN ADVANCED PROSTATE CANCER
Androgen receptor as a predictor to response to androgen deprivation therapy
A consensus has been reached by investigators who have reported upon the use of AR
immunostaining to predict prognosis of patients with advanced CaP treated with ADT.
Barrack’s group first postulated that lack of response to ADT would be indicated by reduced
levels of expression of AR. However, they reported that the mean AR concentration per nucleus
and the mean percentage of AR-positive nuclei did not differ between responders and non-
responders to ADT.[39] However, they subsequently reported that the heterogeneity of
expression of AR predicted response to ADT.[25] A series of studies that took advantage of
the ability to examine archival tissue and to more precisely quantitate AR expression using
image analysis techniques have confirmed these results. Tilley’s group used video image
analysis and an affinity-purified polyclonal antibody directed against the N terminus of AR to
predict perfectly the outcome after ADT of 21 patients with advanced CaP.[21] They found
that more precise measurement of AR expression allowed development of a classification
algorithm, but this algorithm has not been evaluated in another patient group or by others.
Another group examined 63 frozen CaPs using a polyclonal AR antibody and found that 48%
of samples had at least 10% AR-positive cells, and these patients responded better to ADT and
survived longer, whereas Gleason grade, clinical stage, and ethnicity were not prognostic.
[17]
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Takeda et al. studied visually frozen prostate biopsy specimens using a polyclonal AR antibody
and calculated AR content as the ratio of positively stained cells to total number of cells.[40]
They reported that AR content was related to the presence of bone metastasis. Patients whose
tumors were composed of cells that exceeded the mean AR content of 48% all responded to
therapy. Careful examination of the paper reveals that the distribution of AR positivity was so
great and the non-responders so few that it is unlikely that prognosis of individual patients
could be predicted on the basis of AR content. Finally, Prins et al[41] and Nabi et al[42] reported
similar results in 45 patients from New York and 85 patients from India, respectively, using
archived specimens, antigen retrieval, and similar image analysis and receptograms. Almost
all patients who had a high percentage of cells immunonegative for AR had no response, or
only a short-term response, to ADT. A consensus seems to have been reached that the presence
of a large number of cells that lack AR expression or have a low level of AR creates sufficient
heterogeneity in the tumor that response to ADT is poor. Such patients may benefit from early
application of chemotherapy.
Androgen-receptor immunostaining in castration-recurrent prostate cancer
The frequency of low-level expression of AR in androgen-stimulated advanced CaP suggested
the hypothesis that castration-recurrent CaP is composed of CaP cells that lack AR expression,
since it was thought that castration-recurrent CaP did not depend on androgens and hence did
not require AR for growth. However, immunohistochemistry suggested that AR expression
was similar in castration-recurrent CaP and androgen-stimulated BPH and CaP.[43] AR
immunostaining of 19 specimens of castration-recurrent CaP (% positive nuclei, 83.7 ± 11.6,
and MOD, 0.284 ± 0.115) was similar to 16 specimens of benign prostate (% positive nuclei,
77.3 ± 13.0, and MOD, 0.315 ± 0.044) (P = 0.25 for % positive nuclei and 0.48 for MOD)
(Figure 1).[3] The finding that AR protein levels were similar in archived specimens of
castration-recurrent CaP and benign prostate when measured using a monoclonal AR antibody
and automated image analysis was similar to earlier reports that used qualitative methods.
[44,45] High levels of AR expression in castration-recurrent CaP in the absence of testicular
androgens provides the potential for enhanced AR sensitivity to available androgens or
alternate mechanisms of activation that would allow AR to remain central to growth regulation
of castration-recurrent CaP.[46–49] These surprising findings suggested to many that AR plays
a critical role in castration-recurrent CaP.[46–48,50] A critical role for AR in castration-
recurrent CaP was supported by three critical preclinical observations. First, intracellular
injection of AR ribozyme decreased the growth of androgen-independent LNCaP cells.[48]
Second, AR over-expression by amplification was common to all castration-recurrent CaP
xenografts studied. [51] Finally, preventing AR nuclear translocation or ligand binding delayed
CaP recurrence in xenograft models.[51]
The mechanisms demonstrated for castration recurrence in preclinical studies have been found
to be relatively rare causes of castration recurrence in studies of clinical specimens. For
example, in contrast to early reports where AR mutations were common, [52] the true frequency
of AR mutations in castration-recurrent CaP is approximately 5%, but may be as high as 30%
in bone-marrow metastasis from patients having prolonged treatment with anti-androgens.
[53] Although AR gene amplification is common[54,55] in castration-recurrent CaP, and AR
amplification was associated with approximately a 50% increase in the amount of AR protein
expressed per cell, survival of CaP patients with amplification was similar to those without
amplification. Finally, several laboratories continue to investigate preclinically ligand-
independent AR activation and even AR-independent androgen-regulated gene expression
although little data suggests that either of these mechanisms for growth occur clinically.
Newer theories for the development of castration-recurrent CaP require examination. First, AR
responds to castration with molecular and biochemical alterations that cause hypersensitivity
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to low levels of ligand. Our group was the first to demonstrate that AR in androgen-independent
CaP cell lines was hypersensitive. AR was approximately four logs more sensitive to
androgens. [56] A biochemical explanation was offered: the AR coactivator profile changed
from SRC-1 toward TIF-2, a finding that was true both in vitro and in clinical specimens.
[57] Further clinical relevance to this finding was suggested recently by Agoulnik et al[58]
who reported that levels of TIF-2 expression were prognostic when combined with levels of
AR expression in men with clinically localized CaP treated by radical prostatectomy. A newer
biochemical mechanism for hypersensitization of the AR in the face of low ligand availability
has been suggested by Guo et al[59] who reported that phosphorylation of Y534 by a Sarc
tyrosine kinase hypersensitized AR to low levels of androgen and was a common characteristic
of clinical specimens of castration-recurrent CaP. Similar findings were found at Y267 and
Y363, which were phosphorylated by ACK1 tyrosine kinase, which was also increased in
clinical samples of castration-recurrent CaP.[60]
ACCURATE MEASUREMENT OF ANDROGEN-RECEPTOR EXPRESSION IN
CLINICAL SPECIMENS
Immunohistochemistry for androgen receptor
The preceding sections should demonstrate that the relevance of AR to clinical CaP is difficult
to determine due to variation (and often errors) in clinical samples chosen for analysis,
immunostaining methodological details, antibodies, assessment of AR content, and outcome
uncertainty. Biochemical measurement of AR protein content in clinical specimens is
impractical due to variation in the relative contribution of epithelia, endothelia and stroma; the
increasingly small size of CaP; multifocality of CaP; and heterogeneity of AR expression
among cells, glands and tumors. Immunohistochemistry upon fresh or frozen prostate tissues
is made difficult by the small specimen size and the difficulty of gross recognition of CaP. The
first study of AR protein expression in prostate tissue used frozen sections, visual scoring, and
a polyclonal antibody.[19]
The discovery of methods for antigen retrieval from archived clinical specimens[61] and the
development of a highly specific monoclonal antibody allowed correlation between AR protein
expression and clinical parameters of interest. Antigen retrieval is best performed using Reveal
Citra buffer (Biocare Medical, Walnut Creek, CA, USA) and a pressurized antigen-decloaking
chamber for 2 minutes at 120°C and 21 PSI. Monoclonal antihuman AR antibody F39.4.1
(Biogenex, San Ramon, CA, USA) has consistently yielded superior results. Other AR
antibodies should be used only after careful optimization, and results using other AR antibodies
should be interpreted with caution. Benign and malignant tissues and appropriate controls
should be immunostained in a single batch. Special care must be taken when studying tissue
microarrays. Tissue microarrays constructed from 2 mm cores can be placed on standard slides,
but 1.0 mm or 0.6 mm cores require polymerized slides. Use of polymerized slides allows
1000-fold dilution of primary antibody but increases background, which makes pathologists
less comfortable interpreting histology. Image analysis is unaffected since background is
subtracted.
AR immunostaining in individual tissue samples cannot be evaluated properly using the
standard 0 to 3+ ‘gestaldt’ assigned by clinical pathologists or laboratory technicians. A visual
scoring technique was developed that assessed intensity of AR immunostaining on a scale of
0 (none) to intense (3+) for each of 100 randomly selected nuclei. This scoring system
attempted to capture overall immunostaining intensity and heterogeneity of AR protein
expression. However, recognition of malignant nuclei required a skilled pathologist or a highly
trained technician and visual assignment of immunopositivity is subjective, tedious, and poorly
reproducible. Mean optical density (MOD) measured using image analysis was found to be
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more accurate and reproducible for measuring AR expression, but object identification
remained difficult. Investigators used a light pen to encircle[25] or a sampling window[41] to
select areas of malignant nuclei for optical density measurement. However, these interactive
image analysis methods were tedious, and user bias influenced the measurements. Tilley et al
[21] used an automated color video image analysis system to measure MOD of each positively
stained area in visually marked malignant tissue. MOD was calculated as the total integrated
optical density divided by the area. Such measurements tend to be less accurate when compared
to MOD measured from individual nuclei. In addition, MOD depends on variability of
immunostaining intensity among tissue sections and tissue thickness.[21,25,41] However, the
need to capture relatively small differences in levels of AR protein expression made precise
measurement of AR protein expression essential for proper investigation of the clinical
relevance of AR to CaP.
Quantitative image analysis for androgen receptor
In order to quantify AR accurately, primary antibody concentration, DAB concentration and
DAB incubation time (5.25 minutes) were optimized to achieve a linear relationship between
AR protein content and optical density of immunoperoxidase–DAB reaction product.[16]
Next, prostatic epithelial nuclei are segmented from complex histological images and nuclei
classified as malignant or benign. This step presents the primary obstacle to accurately
quantifying AR expression using image analysis. The barrier was overcome by combining
segmentation algorithms and nuclear morphometry.[62]
Images are acquired at total magnification of at least 400×. Each image consists of 640 × 480
pixels collected in 24-bit color mode (16.7 million colors) and is stored in an uncompressed
tagged image format file (TIFF). The resolution for digital images is 0.13 µm/pixel (1500×).
The image analysis system was developed on networked DEC 5000 workstations, and uses
programs written in C++, Windows-based Statgraphics 4.1 and Optimas 6.0.[16,63,64] The C
++ programs incorporated graphics and image processing libraries (IGLOO). [65] The image
analysis programs were later ported to a PC-compatible system on a Linux platform. However,
images were collected using Windows-based systems that required image transfer across
platforms. The current image-analysis software was developed on a Java platform (Java
Runtime Environment, Sun Microsystems, Santa Clara, CA, USA) and incorporates all features
of previous versions. The software eliminates the need for Statgraphics and Optimas and can
be deployed on a variety of platforms with several versions of the software running at the same
time without conflict.[66] The program is associated with a Web browser and can be
downloaded freely from our website.[67] Once downloaded, Web connection is no longer
required. Nuclear boundaries are extracted automatically using our segmentation algorithms.
[65,68] A segmented object is classified as ‘malignant epithelial nucleus’ or ‘object of no
interest’ using a classification algorithm according to hue, size, and shape.[62] The optical
density of immunoperoxidase–DAB product is measured using an image subtraction technique
at the maximum absorption wavelengths.[69] AR immunostaining is described by optical
density and per cent AR positivity.[16] Twenty images (approximately 1500–2000 nuclei)
provided an adequate sample size, since the average deviations from the MOD for a specimen
remained within 5% upon collection of additional images.
Human intervention is only required to create a set of classification parameters. These
parameters are used to reduce the effect of local variations in slide preparation and image
acquisition on nuclear measurements. This system is superior to commercially available image
analysis software, such as Adobe Photoshop,[70] Optimas,[42] and Image Pro Plus,[71] which
contain macros that allow semi-automated image analysis. User interaction is required for
object (nuclei) selection, modification of object boundaries, and/or selection of thresholds.
Dedicated image analysis systems such as CAS-200,[72] ACIS[73] and Autocyte[74] consist
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of hardware and proprietary software which typically require user interaction and cannot be
modified for this application.
Potential pitfalls must be avoided. Commercial reagents used for immunostaining are not
standardized, and thus immunostaining patterns differ among research laboratories. When
combined with local variations in image acquisition, the resulting automated analysis may
produce significant errors. A set of classification parameters must be generated to calibrate the
nuclear analysis software with each new dataset that makes the automated image analysis
software independent of the type of immunostaining or imaging system used. Discriminant
analysis of grayscale histograms of red, green and blue color information determines optimal
thresholds for automated segmentation of red, green and blue images that is necessary to
segment nuclei from a complex histological image.[75,76] The hue, saturation and intensity
component images are multiplied by their corresponding discriminant coefficients from the
parameter file and combined to form a single image. A nuclear mask is applied to the image
and the resulting nuclear areas are classified as immunopositive or immunonegative depending
on their classification score.
Practice points
• prostate cancer, compared to benign prostate, exhibits decreased intensity and
greater heterogeneity of androgen-receptor protein expression
• prostate cancer that is associated with higher levels of androgen-receptor protein
expression, and loss of androgen-receptor protein expression within the
peritumoral stroma is associated with higher tumor volume at presentation and
higher failure rate of potentially curative therapies
• androgen-receptor protein expression is higher in the benign prostate and even
higher in prostate cancer from African Americans compared to Caucasian
Americans, and is the only potentially relevant biological difference found
between the races that is likely to contribute to the more than two-fold higher
mortality of prostate cancer in African Americans
• prostate cancer that recurs during androgen deprivation therapy expresses
androgen-receptor protein at levels similar to those expressed in androgen-
stimulated benign prostate; these surprising findings have led to intensive
investigation of the critical role for the androgen receptor in castration-recurrent
prostate cancer
Research agenda
• the molecular mechanism responsible for the increased expression of androgen-
receptor protein in more aggressive prostate cancers and in the benign and
malignant prostate of African Americans requires further study
• androgen-receptor mutations, androgen-receptor gene amplification, ligand-
independent androgen-receptor activation, and even androgen-receptor-
independent androgen-regulated gene expression appear to play limited roles in
the progression of prostate cancer to castration-recurrent prostate cancer
• intensive investigation of the hypersensitization to the androgen receptor, which
enables transactivation in the absence of circulating testicular androgens, should
be undertaken
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• further study is required for the mechanism of production of tissue androgen levels
sufficient for androgen-receptor activation in prostate cancer that recurs during
androgen-deprivation therapy
• androgen-receptor immunohistochemistry is technically difficult. Assessment of
androgen receptor, in order to be quantitative, requires proper antigen retrieval,
establishment of linear relationships between androgen-receptor expression and
immunostaining, and accurate and reproducible measurement of androgen-
receptor expression. Further research should establish an optimal method for
measurement of androgen-receptor expression, which almost certainly must be
performed using video color image analysis
• the difficulty of procuring specimens of castration-recurrent prostate cancer for
study, especially serially during treatment of patients with advanced prostate
cancer, requires a commitment by physicians and patients to research, rapid
procurement, and optimal storage of these invaluable specimens
CONCLUSION
One must accept that the AR plays an important role in the development and progression of
CaP and appears critical to the growth of castration-recurrent CaP in spite of castrate levels of
circulating testicular androgens. Further study of the role of AR is made difficult by several
factors. First, the evaluation of AR function in vitro requires highly artificial situations where
AR reporter constructs must be cotransfected, and often wild-type AR must be cotransfected.
Second, the literature is hopelessly confused by careless use of terminology and difficulties in
measuring androgen levels. Androgen-sensitive and androgen-independent growth are often
not used carefully, androgen absence and androgen depletion are confused, and different types
of androgen deprivation therapy are often used interchangeably when they may not be
equivalent. AR is labile and subject to tissue ischemia and fixation differences before one even
begins to attempt quantitation using immunohistochemistry. Immmunohistochemical
assessment is made difficult by all the different means of quantitatively assessing AR
expression. Visual scoring systems are almost as numerous as the number of laboratories
assessing AR immunostaining. AR measurement using image analysis is made difficult by the
relative lack of programs available to segment nuclei from complex immunohistochemical
images. Once segmented, malignant nuclei must be properly segregated from other nuclei.
Once malignant epithelial nuclei are segregated, AR protein expression must be measured
accurately. In order to more properly establish the role of AR in clinical CaP, a better
appreciation must be obtained of the differences between AR expression and function in vitro
and in vivo. Unfortunately, in vitro study of AR may more often confuse than inform. Although
closer to the clinical situation, study of clinical specimens all too often is done with lack of
precision that may make the recognition of subtle differences in AR expression and activation
difficult. These difficulties may preclude recognition of subtle differences in AR expression
that may provide biomarkers of CaP aggressiveness or treatment failure. Lastly, the preclinical
and clinical data all suggest that AR plays a critical central role in castration-recurrent CaP.
Difficulty in procuring specimens of castration-recurrent CaP for study, especially serially
during treatment of patients with advanced CaP, slows progress in the field.
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Androgen-receptor protein expression is similar in androgen-stimulated benign prostate (left)
and castration-recurrent prostate cancer (right).
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